By removing the requirement for animal use and human infection, Prellis can identify hundreds of high-quality antibody candidates that bind to pathogens, cancer, and autoimmune disease target proteins in just 20 days.
Externalized Immune System platform (EXIS™) is the first de novo therapeutic discovery system in synthetic human tissue and allows for rapid high-quality human antibody discovery in 20 days.
Using lymphocytes isolated from a healthy blood donation, Prellis recreates the human immune system in the form of a three-dimensional lymph node organoid. Once the lymph node organoid is established, antigens are introduced in a vaccine-like-cocktail to elicit B cell class switching, somatic hypermutation, and memory B cell formation.
EXIS™ antibodies are IgG antibodies, that exhibit class-switched recombination and somatic hypermutation. EXIS™ technology generates high potency novel antibodies with picomolar binding affinities as well as antibodies with high sequence similarity to virus neutralizing antibodies that typically require screening of hundreds of human patients.
As companion technology to EXIS™, Prellis has developed the Antibody Finder algorithm which leverages the nature of whole tissue development of B cells into high affinity clonal pools. Antibody Finder yields a 4x-increase in identification of high affinity antibodies relative to traditional single cell sequencing analysis.
Antibody discovery typically requires 5-9 months in animal models. EXIS™ reduces discovery time of therapeutic-quality fully human antibodies to less than 3 weeks. Single cell sorting of B cells from a large population of people infected with SARS-CoV-2 have allowed for screening of circulating B cells from a human infected with a pathogen. However, screening of infected patients is limited and low through-put relative to ultrafast development in lymph node organoids. Furthermore, single cell sorting lacks tissue-resident B cell information such as clonality and the ability to characterize the quality of the human immune response.
Internal Prellis Programs
Since the advent of the COVID19 pandemic, Prellis has isolated over 730 unique human antibodies that are active against the SARS-CoV-2 spike protein. Similar to antibodies isolated from infected donors Prellis antibodies demonstrated convergence on known neutralizing CDRs. Prellis is currently moving top antibody candidates with picomolar binding affinities through IND enabling studies.
Synthetic human lymph nodes and the EXIS™ platform were developed by Prellis founder and CEO, Melanie Matheu, PhD.
Dr. Matheu has over 15 years of research experience in Immunology and thousands of citations of her peer reviewed work characterizing cell-cell interactions in living tissues during immune responses. Prellis Biologics, Inc. holds exclusive rights all intellectual property related to the EXIS™ platform. (US Patent Issued, December 2019)
Influenza A causes up to 80,000 deaths annually in the US. Often, a novel influenza strain threatens to develop pandemic potential. In three weeks Prellis generated a library of 300,000 unique antibodies that are active against either the H1, H3, or both H1 and H3 of 2020 predicted Influenza A strains. Currently Prellis is screening 30 antibodies for in vivo efficacy. In addition, we are investigating a set of promising antibodies that bind to H1, H3, H5, and H7 as part of a discovery effort for a pan-neutralizing antibody.
Marburg Hemorrhagic Fever
Prellis has isolated 88 potentially neutralizing human antibodies against the Marburg Hemorrhagic Fever, a cousin of the Ebola virus. Marburg is a high lethality (up to 88% death rate) virus that has the potential to become a pandemic virus. There are currently no known therapeutics that are effective against Marburg Hemorrhagic Fever. Prellis is working closely with a partner to finalize the neutralizing antibodies for clinical development.